retatrutide gip glp-1 glucagon receptor agonist PDB-101: Molecule of the Month: Agonists How Does Retatrutide Work? Doctor

108 Another retrospective study reported that in a population with T2DM and previously diagnosed MASLD/MASH, GLP-1RA is associated with a decreased incidence of hepatocellular carcinoma (HCC) and a reduced risk of hepatic decompensation events compared with other antidiabetic agents

Future research could aim to develop positive-side-effect and negative-side-effect drugs to neutralize adverse effects, thus alleviating patient discomfort during treatment

The starting dose period occupies the first 4 to 8 weeks

In rare cases, this can increase the risk of regurgitation and aspirationstomach contents going into the lungswhich can lead to pneumonia, prolonged hospital stay, or even intensive care